1. Home
  2. NBIX vs CACI Comparison

NBIX vs CACI Comparison

Compare NBIX & CACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NBIX
  • CACI
  • Stock Information
  • Founded
  • NBIX 1992
  • CACI 1962
  • Country
  • NBIX United States
  • CACI United States
  • Employees
  • NBIX N/A
  • CACI N/A
  • Industry
  • NBIX Biotechnology: Biological Products (No Diagnostic Substances)
  • CACI EDP Services
  • Sector
  • NBIX Health Care
  • CACI Technology
  • Exchange
  • NBIX Nasdaq
  • CACI Nasdaq
  • Market Cap
  • NBIX 14.4B
  • CACI 11.7B
  • IPO Year
  • NBIX 1996
  • CACI 1979
  • Fundamental
  • Price
  • NBIX $150.87
  • CACI $589.27
  • Analyst Decision
  • NBIX Strong Buy
  • CACI Strong Buy
  • Analyst Count
  • NBIX 18
  • CACI 13
  • Target Price
  • NBIX $172.06
  • CACI $601.91
  • AVG Volume (30 Days)
  • NBIX 1.0M
  • CACI 270.9K
  • Earning Date
  • NBIX 10-28-2025
  • CACI 10-22-2025
  • Dividend Yield
  • NBIX N/A
  • CACI N/A
  • EPS Growth
  • NBIX 12.44
  • CACI 12.06
  • EPS
  • NBIX 4.19
  • CACI 22.62
  • Revenue
  • NBIX $2,682,700,000.00
  • CACI $8,858,558,000.00
  • Revenue This Year
  • NBIX $23.68
  • CACI $10.71
  • Revenue Next Year
  • NBIX $18.02
  • CACI $5.73
  • P/E Ratio
  • NBIX $35.78
  • CACI $26.05
  • Revenue Growth
  • NBIX 19.61
  • CACI 12.61
  • 52 Week Low
  • NBIX $84.23
  • CACI $318.60
  • 52 Week High
  • NBIX $157.67
  • CACI $596.95
  • Technical
  • Relative Strength Index (RSI)
  • NBIX 59.16
  • CACI 68.80
  • Support Level
  • NBIX $133.62
  • CACI $573.19
  • Resistance Level
  • NBIX $157.67
  • CACI $596.49
  • Average True Range (ATR)
  • NBIX 4.58
  • CACI 19.32
  • MACD
  • NBIX 0.98
  • CACI 1.72
  • Stochastic Oscillator
  • NBIX 67.98
  • CACI 90.41

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

About CACI CACI International Inc.

CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.

Share on Social Networks: